Brought in to bring strategic insight and perspective to early and mid-stage biotech companies.Drives and delivers business-critical results:• Project Leader on 12 consulting projects coordinating cross-functional expertise in clinical, regulatory, and CMC. Projects were completed on time, on budget, and to customer satisfaction.• Created an investor pitch deck for a client including a strategic narrative and business case. The client raised over $15M in a difficult funding environment.• The Lead Consultant on a due diligence project. Developed “external” financial valuation to verify seller’s claims. Analysis revealed optimistic assessments of commercial potential and late-stage clinical costs.• Consultant on data integrity project where Ph3 data collection procedures and data were audited for fraudulent activity. Identified probable cause for malicious activity.• Leader of internal working group to create AI/ML strategy and vision.Business-critical strategic planning initiatives include:• Creating integrated development plans including timelines, budgets, milestones, and risk assessments. • Conducting assessment and prioritization to balance risk, timing, and opportunity.• Performing competitive landscape analysis and primary research with KOLs.• Identifying trends for licensing and acquisition deals. • Building target product profiles for optimal positioning.• Performing asset due diligence for investors including financial valuation. • Optimizing governance systems to improve decisions with accountability.• Improving Investor pitch deck and providing guidance on approaching investors.

Retained with increasing responsibilities through company transitions from GD Searle to Pharmacia to Pfizer. Internal consulting role guiding strategic planning and facilitating tough investment and trade-off decisions.Business-critical results:• Breast Cancer Therapy: Led fast-to-market strategy and business case resulting in a launch 18 months ahead of the competition and over $1B in year 1 sales.• Non-Opioid Pain Therapy: Led strategic asset maximization process for the initial Phase 3 strategy with multiple indications at launch.• Celebrex and Lyrica: Created lifecycle strategy initiatives that built brands from an initial $2B to over $6B in annual revenue.Business-critical strategic planning initiatives included:• Prioritizing the $6.5B R&D budget. Led Asset teams through the prioritization process for the development of buy-up and life-cycle strategies. Built business cases for each investment proposal. • Guided senior leadership on investment fit with overall strategy, impact and risks to budget / LRF, and final buy-up or buy-down recommendation. • Leader and thought partner for strategic initiatives and processes to guide decisions related to strategy formulation, resource allocation, risk management, and portfolio optimization.• Facilitating the development of strategic options by implementing decision analysis methodologies to evaluate alternatives incorporating relevant cost, risk, and return inputs.Led the forecast development on key assets including Tanezumab and Ibrance.